Clinical Trials Browser

Neoplasm Metastasis × Topotecan × Gynecologic × Clear all

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT01012817 2025-09-15

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Phase 1/2 Active not recruiting

88 enrolled 23 charts

Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Phase 1 Terminated

221 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT02100007 2017-10-02

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

Phase 1/2 Terminated

46 enrolled 17 charts

GynecologicThoracic

Neoplasm Metastasis, Ovarian Neoplasms, Recurrence, Small Cell Lung Carcinoma

NCT00770536 2015-09-29

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Phase 1 Completed

103 enrolled

Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms

Clinical Trials

FRAmework-01

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR